Profound Medical (TSX-V:PRN) has completed a bought deal offering of 15.82 million common shares at a price of $1.10 each for gross proceeds of about $17.4-million. The offering was completed through a syndicate of...
Avivagen (TSX-V:VIV) has signed an agreement with Shaanxi Jintai Mining, a widely diversified Chinese company, to form a joint venture company to commercialize OxC-beta Livestock in China. The JV will initially target...
BioTuesdays’ Stephen Kilmer joins Titan management, directors and guests at the bell closing ceremony. Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP)...
After an end-of-Phase 2 meeting with the FDA, Aurinia Pharmaceuticals (NASDAQ:AUPH) plans to begin a single Phase 3 clinical trial for voclosporin in the treatment of lupus nephritis (LN). Aurinia believes the Phase 3...
Closely-held Turnstone Biologics has completed a $41.4-million series B financing led by new investor, OrbiMed, with participation from another new investor, F-Prime Capital Partners, and existing investors, FACIT and...
Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week. Probuphine, a subdermal implant...
Closely-held Mati Therapeutics has been granted a U.S. patent covering a method of providing a sustained drug release to an eye using a proprietary punctal plug design placed in the punctum (tear duct) over a treatment...
Avivagen (TSX-V:VIV) has made the first industrial-scale sale of its OxC-beta livestock to UNAHCO in the Philippines. The sale is for 150 kilograms of OxC-beta livestock 10% premix at pricing in line with...
Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine implant has been recognized as one of the “12 Most Important Innovations of the Year” in the health category in Popular Science’s annual Best of...
Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials – OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic...
3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company’s first step toward validation and approval of...
Avivagen (TSX-V:VIV) has agreed to supply OxC-beta Livestock to UNAHCO for sales and distribution in the Republic of the Philippines. OxC-beta has been shown to be effective and economic in replacing the antibiotics...
Microbix Biosystems (TSX:MBX) expects to report revenue in the range of $3.3-million for the fiscal fourth quarter ended Sept. 30, 2016, an increase of 57% from $2.1-million in the year earlier quarter. Fourth quarter...
Profound Medical (TSX-V:PRN) has entered into an agreement with a syndicate of underwriters, led by GMP Securities, for a bought deal of 15.82 million common shares at a price of $1.10 each for gross proceeds of $17.4...
Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids. Independent TV station, WHDT...
Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular...
The U.S. Patent and Trademark Office has issued a patent to Mateon Therapeutics (NASDAQ:MATN) and Baylor University that covers compounds which modulate cathepsin activity, particularly cathepsin L or cathepsin K, and...
Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the company reported additional positive data for its voclosporin drug candidate in patients with active lupus nephritis...
Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current...
Profound Medical (TSX-V:PRN) has received Frost & Sullivan’s 2016 European Prostate Ablation Systems New Product Innovation Award for its TULSA-PRO system. TULSA-PRO, which received CE Mark approval in April 2016...
Dipexium Pharmaceuticals (NASDAQ:DPRX) has been granted small and medium enterprise (SME) designation by the European Medicines Agency (EMA). The company recently completed its pivotal Phase 3 clinical trials...
Cellectar Biosciences (NASDAQ:CLRB) reported positive data from the second cohort of patients enrolled in its orphan-drug designated Phase 1 study of CLR 131 in patients with relapsed or refractory multiple myeloma...